ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1564

Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis
Abstract Number: 1519

Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Abstract Number: 0218

Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population
Abstract Number: 2397

Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Abstract Number: 2070

Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Abstract Number: 0957

Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Abstract Number: 0032

Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis
Abstract Number: 2121

Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Abstract Number: 1150

Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies
Abstract Number: 1330

Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
Abstract Number: 1153

Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Abstract Number: 0954

Increased Proliferating Natural Killer Cells Exhibit an Aberrant Pro-Inflammatory Gene Signature in Systemic Sclerosis Patients
Abstract Number: 2078

Increased RAGE Expression in Myositis
Abstract Number: 2339

Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
Abstract Number: 1024

Increased Social Vulnerability Index Predicts Lower Likelihood of Remission in Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].